methoxamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1753 | 390-28-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.58 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | GLAXOSMITHKLINE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01CA10 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D000322 | Adrenergic Agonists |
| MeSH PA | D058646 | Adrenergic alpha-1 Receptor Agonists |
| MeSH PA | D000316 | Adrenergic alpha-Agonists |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D013566 | Sympathomimetics |
| MeSH PA | D014662 | Vasoconstrictor Agents |
| CHEBI has role | CHEBI:35569 | alpha-adrenergic agonists |
| CHEBI has role | CHEBI:137431 | antihypotensive agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Low blood pressure | indication | 45007003 | |
| Paroxysmal supraventricular tachycardia | indication | 67198005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.7 | acidic |
| pKa2 | 8.68 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-1A adrenergic receptor | GPCR | AGONIST | EC50 | 5.10 | WOMBAT-PK | CHEMBL | |||
| Alpha-1D adrenergic receptor | GPCR | AGONIST | EC50 | 4.90 | WOMBAT-PK | CHEMBL | |||
| Alpha-1B adrenergic receptor | GPCR | AGONIST | Ki | 4 | IUPHAR | CHEMBL | |||
| Alpha-1D adrenergic receptor | GPCR | AGONIST | Ki | 4.50 | IUPHAR | ||||
| Adrenergic receptor alpha-2 | GPCR | IC50 | 5.44 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019829 | VUID |
| N0000147917 | NUI |
| D01020 | KEGG_DRUG |
| 61-16-5 | SECONDARY_CAS_RN |
| 4018779 | VANDF |
| 4019829 | VANDF |
| C0025681 | UMLSCUI |
| CHEBI:6839 | CHEBI |
| CHEMBL524 | ChEMBL_ID |
| DB00723 | DRUGBANK_ID |
| D008729 | MESH_DESCRIPTOR_UI |
| 6082 | PUBCHEM_CID |
| 483 | IUPHAR_LIGAND_ID |
| 209 | INN_ID |
| HUQ1KC1YLI | UNII |
| 203187 | RXNORM |
| 5079 | MMSL |
| d00703 | MMSL |
| 001798 | NDDF |
| 004723 | NDDF |
| 21303006 | SNOMEDCT_US |
| 372769005 | SNOMEDCT_US |
| 54406003 | SNOMEDCT_US |
| CHEMBL1201103 | ChEMBL_ID |
Pharmaceutical products:
None